ClinicalTrials.gg
CompletedNCT03112681EPICSUpdated Sep 19, 2024Results posted

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

A Phase 2 interventional study of Saroglitazar magnesium 2 mg and Saroglitazar magnesium 4 mg in Primary Biliary Cirrhosis, sponsored by Zydus Therapeutics Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
40th of 65
37 · median 46
Started
2017
with 7 others
Phase 2
34 of 83
2 open now
Registered
37th of 83
by date
Lead sponsor
6 of 83
Zydus Therapeutics Inc.

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 40th largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 37th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis (PBC). A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo.

Read the detailed description

Study SARO.16.004.02 is a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis.

A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo. The primary objective is to investigate the effect of a 16-week treatment regimen of Saroglitazar magnesium 2 mg and 4 mg on alkaline phosphatase (ALP) levels in patients with Primary Biliary Cholangitis.

03

Conditions studied

  • Primary Biliary Cirrhosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, between 18 and 75 years of age, inclusive.
  2. a) Patients on therapeutic doses of Ursodeoxycholic acid (UDCA) for ≥12 months and stable therapy for ≥3 months prior to enrolment.

    OR b) Patients who are unable to tolerate UDCA, and did not receive UDCA for at least 3 months from the date of screening.

  3. History of confirmed Primary Biliary Cholangitis Diagnosis, based on American Association for the Study of Liver Disease [AASLD] and European Association for Study of the Liver [EASL] Practice Guidelines; [Lindor 2009; EASL 2009], as demonstrated by the presence of at least≥2 of the following 3 diagnostic factors:

    • History of elevated Alkaline Phosphatase levels for at least 6 months prior to Screening Visit 1
    • Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (\<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex])
    • Liver consistent with PBC.
  4. ALP ≥1.67x (ULN) at Visit 1 and Visit 2 and with \< 30% variance between the levels from Visit 1 to Visit 2.
  5. : Female patients must be , surgically sterile, or if premenopausal, agree to use ≥ 1 effective method of contraception during the trial. Effective methods of contraception are considered to be Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection); or Double barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with spermicide; or Intrauterine device (IUD); or Vasectomy (partner).
  6. Must provide written and agree to comply with the trial protocol.

Exclusion criteria

Exclusion Criteria:

  1. Consumption of >3 units of alcohol per day (>21 units per week) if male and >2 units of alcohol per day (>14 units per week) if female for at least 3 consecutive months in the last 5 years (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).
  2. History or presence of other concomitant liver diseases including:

    • or C virus (, HBV) infection
    • Primary sclerosing cholangitis (PSC)
    • Alcoholic liver disease
    • Definite liver disease or overlap syndrome
    • Non-alcoholic steatohepatitis (NASH)
  3. Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, > 2x , ascites, encephalopathy, known esophageal varices or history of variceal bleeding and active or history of hepatorenal syndrome.
  4. History of any venous thromboembolism, (TIA), intracranial hemorrhage, neoplasm, arteriovenous malformation, vasculitis, bleeding disorder, coagulation disorders or screening blood tests that indicate altered coagulability (e.g. count, [aPTT], partial thromboplastin time [PTT] or thrombin time [TT] tests).
  5. Patients with INR > upper limit of normal (ULN) at visit 1.
  6. Patients with total bilirubin > ULN at visit 1 that is not due to Gilbert's syndrome
  7. Patients with >30% increase in , total bilirubin, or Internation normalized ratio (INR) between Visit 1 to Visit 2.
  8. Patients with serum creatinine >ULN according to the gender at Visit 1.
  9. Patients with abnormal total creatine kinase (CK) OR lipase OR amylase at Visit 1.
  10. Unstable cardiovascular disease, including:

    • unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the past 3 months), acute coronary syndrome within the past 6 months, acute myocardial infarction in the past 3 months or heart failure of class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the past 6 months
    • history of (within prior 3 months) or current unstable cardiac dysrhythmias
    • uncontrolled hypertension (systolic blood pressure [BP] >160 mmHg and/or diastolic BP >100 mmHg)
    • stroke or transient ischemic attack within the prior 6 months
  11. History of in the past 5 years and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer.
  12. to Saroglitazar magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar magnesium.
  13. Known allergy, sensitivity or intolerance to the study drug, comparator or formulation ingredients.
  14. Participation in any other clinical study within the previous 3 months of screening.
  15. Illicit substance abuse within the past 6 months.
  16. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, (HIV), coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Saroglitazar magnesium 2 mg

    Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks

    Drug: Saroglitazar magnesium 2 mg

  • Experimental
    Saroglitazar magnesium 4 mg

    Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks

    Drug: Saroglitazar magnesium 4 mg

  • Placebo comparator
    Placebo

    Placebo tablet Once daily for 16 weeks

    Drug: Placebo Oral Tablet

Interventions

  • Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.

    Also known as: Not any

  • Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.

    Also known as: Not any

  • DrugPlacebo Oral Tablet

    Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.

    Also known as: Not any

06

What researchers measure

Primary outcomes

  1. Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.

    Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.

    Time frame: Baseline and Week 16

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Started141310
Completed13109
Not completed131

Outcome measures

PrimaryEffect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.

Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.

Time frame:
Baseline and Week 16
Reported as:
Mean · U/L
Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.
U/LSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.-163.82 ± 111.84-162.31 ± 113.98-11.15 ± 27.36
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · paired t-test · p = 0.0001
  • Saroglitazar Magnesium 4 mg vs Placebo · paired t-test · p = 0.0002

Adverse events

Collected over 16 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saroglitazar Magnesium 2 mg0/14 (0%)2/14 (14.3%)12/14 (85.7%)
Saroglitazar Magnesium 4 mg0/13 (0%)0/13 (0%)11/13 (84.6%)
Placebo0/10 (0%)0/10 (0%)8/10 (80%)
Most frequent serious events
Most frequent serious events
EventSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Oedema peripheralGeneral disorders1/140/130/10
AppendicitisInfections and infestations1/140/130/10
DyspnoeaRespiratory, thoracic and mediastinal disorders1/140/130/10
Most frequent other events
Showing 10 of 67
Most frequent other events
EventSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
FallInjury, poisoning and procedural complications0/140/132/10
CoughRespiratory, thoracic and mediastinal disorders0/140/132/10
NauseaGastrointestinal disorders1/142/131/10
NasopharyngitisInfections and infestations1/142/130/10
Hepatic Enzyme increasedInvestigations0/142/130/10
ConstipationGastrointestinal disorders2/141/130/10
DyspepsiaGastrointestinal disorders2/140/131/10
Urinary tract infectionInfections and infestations2/141/130/10
Transaminase increasedInvestigations2/140/130/10
DiarrheaGastrointestinal disorders1/141/131/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Mean57.21 ± 9.6755.08 ± 8.0059.20 ± 7.3057.00 ± 8.44
Sex: Female, Male
Sex: Female, Male(Participants)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Female13131036
Male1001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Hispanic or Latino3104
Not Hispanic or Latino10121032
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1113
White1311933
More than one race0000
Unknown or Not Reported0000
Body Mass Index
Body Mass Index(kg/m^2)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Mean27.71 ± 6.3929.62 ± 6.4932.30 ± 7.3729.62 ± 6.77
08

Study locations

9 sites
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Gastrointestional Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Rutgers NJ Medical School
    Newark, New Jersey 07101, United States
  • Carolinas Healthcare System
    Charlotte, North Carolina 28204, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45249, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Einstein Medical Center Philadelphia
    Philadelphia, Pennsylvania 19141, United States
09

References and documents

Publications

  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6. No abstract available. PubMed 19501929 ↗
  • Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906. No abstract available. PubMed 19554543 ↗
  • Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, Shaikh F, Bainbridge JD, Parmar DV, Chalasani NP. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022 Jan;76(1):75-85. doi: 10.1016/j.jhep.2021.08.025. Epub 2021 Sep 4. PubMed 34487750 ↗
  • Vuppalanchi R, Gonzalez-Huezo MS, Payan-Olivas R, Munoz-Espinosa LE, Shaikh F, Pio Cruz-Lopez JL, Parmar D. A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis. Clin Transl Gastroenterol. 2021 Mar 26;12(4):e00327. doi: 10.14309/ctg.0000000000000327. PubMed 33769355 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Aug 2020, 35 months.

Results were first posted in Sep 2024, 4 years 1 month after primary completion.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2017
First posted
Apr 13, 2017
StartActual
Aug 18, 2017
Primary completionActual
Aug 7, 2020
CompletionActual
Aug 7, 2020
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03112681
Responsible party
Sponsor
First posted
Apr 13, 2017
Start date
Aug 18, 2017
Primary completion
Aug 7, 2020
Completion
Aug 7, 2020
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Deven Parmar, MD FACP FCP
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion